Poseltinib

Eli Lilly and its Korean collaborative partner Hanmi stopped a Phase II trial on an experimental rheumatoid arthritis treatment following less-than-stellar interim results. Eli Lilly and Company and its Korean collaborative partner Hanmi Pharmaceutical, Co., Ltd stopped a Phase II trial on an experimental rheumatoid arthritis treatment after less-than-stellar interim results were examined. Although Lilly has remained mum on the trial’s halting, Hanmi broke the news in a regulatory filing , according to Korea Biomedical Review . In a regulatory filing, Hanmi said Lilly opted to discontinue the trial after interim results showed a lack of efficacy. Lilly and Hanmi were studying the effects of a Bruton’s tyrosine kinase (BTK) inhibitor (LY3337641/HM71224) in patients with rheumatoid arthritis. Lilly and Hanmi forged a collaborative agreement for HM71224 in 2015. When the two companies struck the deal worth up to $690 million , they said that in addition to RA the drug would also be explored as a potential treatment for lupus, lupus nephritis, Sjögren’s syndrome, and other related conditions. In its filing Hanmi said the two companies are still looking to develop the drug for those other conditions, Korea BioMedical Review noted in its report today. At the time the two companies struck the deal they expressed hope for HM71224 to have an effect on prevalent autoimmune diseases. “We’re highly encouraged by the potential of HM71224 to deliver an innovative, first-in-class treatment option,” Eli Lilly said at the time the 2015 deal was struck. Shares of Hanmi Pharmaceuticals, which trades on the Korean Stock Exchange, fell about 9 percent on the news of the failure. Hanmi has several developmental partnerships in addition to the collaboration with Eli Lilly. While Hanmi said it will continue to work with Eli Lilly, if the Indianapolis-based company opts to walk away completely it won’t be the first time that’s happened to Hanmi. In October 2016 Boehringer Ingelheim walked away from its $730 million partnership with Hanmi over safety concerns of the cancer drug olmutinib. Rheumatoid arthritis affects an estimated 23.7 million people worldwide. The condition is a chronic inflammatory condition characterized by pain, swelling of the joints, stiffness and disability. There are approximately 1.5 million people in the United States who have been diagnosed with RA. Because of the wide patient population, it’s a popular target for drugmakers. Although Lilly halted the BTK inhibitor trial, the company is still focused on a hoped-for approval of baricitinib. Last year the U.S. Food and Drug Administration rejected the drug over blood clot worries. But then the regulatory agency reversed course and invited the company to resubmit the drug for approval, which it did.

March 20, 2015 By Alex Keown , BioSpace.com Breaking News Staff BEIJING – Eli Lilly and Company inked a $456 million deal with Chinese drugmaker Innovent Biologics, Inc. to develop and market three cancer treatments over the next 10 years, the companies announced Friday. The agreement, one of the broadest collaborations with a Chinese biotech company, creates possible new treatment options for cancer patients, while strengthening the presence of both companies in the Chinese oncology market. Alfonso Zulueta , president of Eli Lilly ’s emerging markets division, said the deal with Innovent “further reinforces our focus to develop collaborative networks to advance research and clinical development in emerging markets.” Under the terms of the deal there are four major components. First, Eli Lily will contribute its cMet monoclonal antibody gene for possible treatment of non-small cell lung cancer however; continue the development of its cMet monoclonal antibody program outside of China. Innovent will contribute its monoclonal antibody targeting protein CD-20 for investigation in hematologic malignancies. Currently Innovent has received investigational new drug approval in China to begin Phase I development for this potential therapy. Innovent will also contribute a pre-clinical immuno-oncology molecule for development in China. Lastly, Eli Lilly wil receive the rights to develop and market up to three pre-clinical bispecific immuno-oncology molecules outside of China. Innovent will receive a $56 million upfront payment from Eli Lilly , with a possible additional $400 million in milestone payments should the drugs reach certain developmental and sales stages. The partnership between the companies strengthens both drugmakers oncology presence in China. Eli Lilly has an established oncology pipeline that includes both small molecules and monoclonal antibodies, which are being studied to treat a wide range of cancers including breast, colorectal, liver and non-small cell lung. Innovent is the first Chinese company to form the type of collaboration the company developed with Eli Lilly , said Michael Yu , Innovent CEO. Eli Lilly has been making inroads into the Asian market by creating partnerships with area drugmakers. In addition to the deal with Innovent , Eli Lilly also inked a $690 million deal with Korea-based Hanmi Pharmaceutical, Co., Ltd to developing Hanmi ’s Bruton’s tyrosine kinase (BTK) inhibitor, HM71224, which is used in the treatment of autoimmune diseases. Last month Eli Lilly pledged $1million commitment to the Ampath Oncology Institute in Kenya to hire additional staff and train healthcare professionals to screen, treat, and provide palliative care to more of the 3.5 million people who live in the region BioSpace Temperature Poll After Amgen Inc. said last week that it will close its South San Francisco facility acquired during its $10 billion buyout of Onyx Pharmaceuticals and will lay off 300 of Oynx ’s 750 workers, BioSpace is wondering—will the number of mergers and acquisitions completed in 2014 mean a “streamlining” of biotech jobs in the Bay Area? Tell us your thoughts. var _polldaddy = [] || _polldaddy; _polldaddy.push( { type: "iframe", auto: "1", domain: "biospace.polldaddy.com/s/", id: "after-amgen-shutters-sf-site-will-bay-area-biotech-bolt", placeholder: "pd_1426521570" } ); (function(d,c,j){if(!document.getElementById(j)){var pd=d.createElement(c),s;pd.id=j;pd.src=(' '==document.location.protocol)?' ':' ';s=document.getElementsByTagName(c)[0];s.parentNode.insertBefore(pd,s);}}(document,'script','pd-embed'));